Fertility Frontiers: What Is a 'Permitted' Embryo in Law?
By Antony Starza-Allen,
Progress Educational Trust
| 06. 13. 2022
The question of what is a 'permitted embryo' under the legislation governing assisted reproduction in the UK has received increasing scrutiny as technological progress challenges the concept of embryohood. As illustrated at Progress Educational Trust (PET)'s event, 'Fertility Frontiers: What Is a 'Permitted' Embryo in Law?', the answer is not solely concerned with the scope of what is permissible in assisted reproduction but goes to the very core of the UK's legislative approach to emerging reproductive technologies.
Introducing the debate, Sarah Norcross, director of PET, highlighted that while UK fertility law gives confidence and security during scientific change, the definition of an embryo, introduced under the Human Fertilisation and Embryology (HFE) Act 2008, is not fully scientifically aligned. Under the HFE Act 2008, an embryo for use in assisted reproduction must have been created by the fertilisation of an unaltered 'permitted egg' with a 'permitted sperm'. It must have no cells added to it from other sources or have its DNA altered (an exception exists for mitochondrial donation). Recent technological developments have, however, challenged... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...